Pembrolizumab

Red

Brand Name(s):KEYTRUDA

Indication:All licensed indications

Rationale:1,2,3

Considered:Aug-15

Review Date:Sep-23

Comments:
Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA428
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
January 2017